Q BioMed Inc.
QBIO · OTC
11/30/2022 | 11/30/2021 | 11/30/2020 | 11/30/2019 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.00 | 0.03 | 0.11 | -0.14 |
| FCF Yield | 271.10% | -35.53% | -25.57% | -17.06% |
| EV / EBITDA | -7.73 | -1.93 | -1.85 | -3.46 |
| Quality | ||||
| ROIC | 679.02% | 452.64% | 1,336.87% | 592.00% |
| Gross Margin | -3.16% | -26.20% | -986.70% | 0.00% |
| Cash Conversion Ratio | -0.95 | 0.52 | 0.46 | 0.40 |
| Growth | ||||
| Revenue 3-Year CAGR | 111.63% | – | – | – |
| Free Cash Flow Growth | 145.13% | 30.98% | -51.85% | 40.94% |
| Safety | ||||
| Net Debt / EBITDA | -6.57 | -0.35 | 0.01 | -0.44 |
| Interest Coverage | -2.49 | -14.58 | -44.38 | -5.49 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 11.09 | 0.00 | 0.00 |
| Cash Conversion Cycle | -2,638.10 | -1,806.89 | -808.07 | -4,759.97 |